AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$XOMA

XOMA Royalty Corp

Price · $XOMAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $XOMA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $XOMA in the last 30 days.

Top stories · $XOMAMore →
MAY 19·Stock TitanMed

BVF group (NASDAQ: XOMA) converts 5,003 Series X preferred into common

BVF group entities converted 5,003 shares of XOMA Royalty Corp's Series X Convertible Preferred Stock into 5,003,000 shares of common stock at $4.03 per share on May 14, 2026. This transaction changed the form of ownership from preferred to common stock for the reporting group, which is a Section 13(d) group owning over 10% of XOMA common stock. The conversions are exempt from short-swing profit rules under Rule 16b-6(b).

APR 1·Stock Titan

XOMA (XOMA) director exercises options, holds 9,234 common shares after trade

XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. These options had been fully vested since July 21, 2017, and are now fully exercised. Following this transaction, Mr. Limber directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.

DEC 25·FOX40 News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

Pomerantz LLP is investigating potential claims against XOMA Royalty Corporation after its development partner, Rezolute, Inc., announced that a Phase 3 study for ersodetug in congenital hyperinsulinism failed to meet its primary and secondary endpoints. This news led to a significant 22.76% drop in XOMA's stock price, prompting the firm to investigate possible securities fraud or unlawful business practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP.

News on $XOMA

All news →